Catalent Pharma Solutions, today announced that Wetteny Joseph has been appointed as its new President, Clinical Supply Services.
Somerset, N.J. – October 22, 2015 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health and global clinical supply services, today announced that Wetteny Joseph has been appointed as its new President, Clinical Supply Services.
Mr. Joseph first joined Catalent in 2008 as Corporate Controller, and in 2012, was charged with leading the finance function for the company’s Modified Release Technologies business unit. In 2013, Mr. Joseph was promoted to Vice President of Finance for Catalent’s Development and Clinical Services division, which included the Clinical Supply Services business unit.
“I have the utmost confidence in Wetteny’s ability to lead our Clinical Supply Services business, in which we have invested significantly over the last few years,” commented Catalent CEO and President, John Chiminski. He added, “Wetteny’s expert contribution to the 2012 acquisition of Aptuit, and more recent major capacity and capability upgrades, have strengthened our global reach in Asia Pacific, increased our overall capacity, and broadened our service offering in the clinical services market.”
Before joining Catalent, Mr. Joseph held senior financial positions at HD Supply, including CFO of a $1.2 billion business unit. He also served as Corporate Controller at Hughes Supply, a Fortune 500 company. In his early career, Mr. Joseph spent six years at PricewaterhouseCoopers as an auditor, and as a strategic financial advisor across a variety of industries.
Mr. Joseph earned both his master’s and bachelor’s degrees in accounting from Florida Atlantic University.
+44 (0)7580 041073
+44 (0) 161 728 5880
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health and global clinical supply services. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,700 people, including over 1,000 scientists, at 31 facilities across 5 continents, and in fiscal 2015 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com.